Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivatuzumab
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bivatuzumab (also known as BIWA 4) is a humanized monoclonal antibody directed against the variant 6 isoform of CD44 (CD44v6), a cell-surface glycoprotein overexpressed in various carcinomas, including squamous cell carcinoma of the head and neck, non-small cell lung cancer, and breast cancer. Developed by Boehringer Ingelheim, bivatuzumab was evaluated in Phase I clinical trials as a naked antibody, as well as a targeting vehicle for radioimmunotherapy when radiolabeled with isotopes such as Rhenium-186 or Technetium-99m. It also served as the antibody component of the antibody-drug conjugate bivatuzumab mertansine. Clinical development of bivatuzumab and its derivatives was halted in 2005 due to severe, dose-limiting skin toxicities, including maculopapular rashes and skin exfoliation, caused by the expression of CD44v6 on normal proliferating epidermal keratinocytes.
- Other names
- bivatuzumabBIWA 4BIWA4BIWA-4
02
Targets
CD44v6 (CD44 variant isoform 6)
Beyond the preview
Go deeper on bivatuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivatuzumab.